• Opinion
• [Reporter's view] Expectations for Revlimid
• by Eo, Yun-Ho Jan 3, 2023 05:41am

• Company
• SK Chemical introduces Lou Gehrig's treatment Teglutik
• by Lee, Seok-Jun Jan 3, 2023 05:41am

• Policy
• The fast track of tx for serious dz without a substitute
• by Lee, Tak-Sun Jan 3, 2023 05:40am

• Policy
• Will Koselugo, a new neurofibroma drug be reimbursed next ye
• by Lee, Tak-Sun Jan 3, 2023 05:40am

• Policy
• Largest-ever drug pricing reeval to be conducted this year
• by Kim, Jung-Ju Jan 2, 2023 06:04am

• Policy
• SK Chemicals Riluzole is listed
• by Lee, Tak-Sun Jan 2, 2023 06:04am

• Policy
• High conc Ultomiris Inj 100mg/mL also approved in Korea
• by Kim, Jung-Ju Jan 2, 2023 06:04am

• Product
• How is the non-face-to-face tx/delivery going overseas?
• by Jan 2, 2023 06:04am

• Company
• U.S. first possible NASH therapy
• by Jan 2, 2023 06:04am

• Company
• The dismissal of 18 employees of Zuellig Pharma is unfair
• by Jan 1, 2023 10:43pm